Optimal sequencing of ibrutinib, idelalisib and venetoclax in patients with chronic lymphocytic leukemia
Phase of Trial: Phase IV
Latest Information Update: 27 Jan 2017
At a glance
- Drugs Ibrutinib (Primary) ; Idelalisib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 27 Jan 2017 Results published in the Annals of Oncology.
- 20 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.